Molecular imaging of proliferation and glucose utilization: Utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer

Annals of Surgical Oncology

Volumn 18, Issue 12, 2011, Pages 3316-3323

  Ott, Katja ^a   Herrmann, Ken ^b   Schuster, Tibor ^c   Langer, Rupert ^b   Becker, Karen ^b   Wieder, Hinrich A ^b   Wester, Hans Jürgen ^b   Siewert, Jörg Rüdiger ^a   Zum Büschenfelde, Christian Meyer ^b   Buck, Andreas K ^b   Wilhelm, Dirk ^b   Ebert, Matthias P A ^b,d   Peschel, Christian ^b   Schwaiger, Markus ^b   Lordick, Florian ^e   Krause, Bernd Joachim ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE; GLUCOSE; KI 67 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; GLUCOSE UTILIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CISPLATIN; DIDEOXYNUCLEOSIDES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; IMMUNOENZYME TECHNIQUES; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 83055179761     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1743-y     Document Type: Article

References (36)

1. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-Fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial [Abstract]. J Clin Oncol (supplement). 2007;25(18 Suppl):15123.
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
3. Lowy AM, Mansfield PF, Leach SD, et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229(3):303-8.
4. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797-805.
5. Siewert JR, Lordick F, Ott K, et al. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg. 2007;246(4):624-8 (discussion 628-31).
6. Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005;103(11):2383-90.
7. Kim SK, Kang KW, Lee JS, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006;33(2):148-55.
8. Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-2-fluoro- D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28(3):247-53.
9. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44(5):690-9.
10. Yun M, Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using (18) F-FDG PET: a comparison study with CT. J Nucl Med. 2005;46(10):1582-8.
11. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21(24):4604-10.
12. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14(7):2012-8.
13. Herrmann K, Ott K, Buck AK, et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med. 2007;48(12):1945-50.
14. Kameyama R, Yamamoto Y, Izuishi K, et al. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2009;36(3):382-8.
15. Weber G, Nagai M, Natsumeda Y, et al. Regulation of de novo and salvage pathways in chemotherapy. Adv Enzyme Regul. 1991;31:45-67.
16. Wells P, Aboagye E, Gunn RN, et al. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst. 2003;95(9):675-82.
17. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer. 2002;94(9):2511-6.
18. Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6(3):159-67.
19. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24(29):4692-8.
20. Machulla HJ, Blocher A, Kuntzsch M, et al. simplified labeling approach for synthesizing 3'-deoxy-3'-[18F]Fluorothymidine ([18F]FLT). J Radioanal Nucl Chem. 2000;243(3):843-846.
21. Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13(12):3552-8.
22. Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40(11):1771-7.
23. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19(12):3058-65.
24. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-30.
25. Roder JD, Bottcher K, Siewert JR, et al. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer. 1993;72(7):2089-97.
26. Siewert JR, Stein HJ, Sendler A, Fink U. Surgical resection for cancer of the cardia. Semin Surg Oncol. 1999;17(2):125-31.
27. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;1(77):147-160.
28. Shah MA, Yeung H, Coit D, et al. A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient outcome. J Clin Oncol. 2007;25:4502
29. Vallbohmer D, Holscher AH, Schneider PM, et al. [18F]-fluorodeoxyglucose- positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol. 2010;102(2):135-40.
30. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30(2):288-95.
31. Mukai K, Ishida Y, Okajima K, et al. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9(3):192-6.
32. Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34(9):1339-47.
33. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714-21.
34. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34(6):878-83.
35. Linecker A, Kermer C, Sulzbacher I, et al. Uptake of (18) F-FLT and (18) F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin. 2008;47(2):80-5 (quiz N12).
36. van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46(3):400-4.